Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬ £¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

Caco-2 ϸ°ûÉøÍ¸ÐÔÊÔÑé

2023-08-08
|
»á¼ûÁ¿£º
arrow.png Caco-2ÉøÍ¸ÐÔ²âÊÔ£¨Caco-2 Permeability Assay£©ÊÇÒ»ÖÖ³£ÓõÄÌåÍâʵÑéÒªÁ죬£¬ £¬£¬ÓÃÓÚÆÀ¹À»¯ºÏÎïÔÚÈËÌ峦µÀÖеÄÎüÊÕˮƽºÍÉøÍ¸ÐÔ¡£¡£¡£¡£¡£¡£

Caco-2ϸ°ûÊÇÒ»ÖÖÈËÀà½á³¦°©Ï¸°ûϵ£¬£¬ £¬£¬³£ÓÃÓÚÄ£ÄâÈËÌåС³¦ÉÏÆ¤Ï¸°û²ãµÄÌØÕ÷ºÍ¹¦Ð§¡£¡£¡£¡£¡£¡£Õâ¸öϸ°ûϵÊ״δÓ1977ÄêÒ»Ãû»¼Óн᳦ÏÙ°©µÄÄÐÐÔµÄÖ×ÁöÖÐÊèÉ¢³öÀ´£¬£¬ £¬£¬±»ÃüÃûΪCaco-2¡£¡£¡£¡£¡£¡£

Caco-2ϸ°û£¨ÈªÔ´--ATCC£©.jpg

Caco-2ϸ°û£¨ÈªÔ´: ATCC£©

Caco-2ÉøÍ¸ÐÔ²âÊÔ£¨Caco-2 Permeability Assay£©ÊÇÒ»ÖÖ³£ÓõÄÌåÍâʵÑéÒªÁ죬£¬ £¬£¬ÓÃÓÚÆÀ¹À»¯ºÏÎïÔÚÈËÌ峦µÀÖеÄÎüÊÕˮƽºÍÉøÍ¸ÐÔ¡£¡£¡£¡£¡£¡£µ±Ò©Îïͨ¹ý¿Ú·þ;¾¶¸øÓèʱ£¬£¬ £¬£¬Ò©ÎïµÄÎüÊÕˮƽºÍÉøÍ¸ÐÔÊÇÖ÷ÒªµÄÒ©´ú¶¯Á¦Ñ§²ÎÊý¡£¡£¡£¡£¡£¡£

»ùÓÚÈËÀà½á³¦°©Ï¸°ûÖêCaco-2µÄÌØÕ÷£¬£¬ £¬£¬¿ÉÒÔͨ¹ýÄ£ÄâС³¦ÉÏÆ¤Ï¸°û²ãµÄÇéÐΣ¬£¬ £¬£¬À´Õ¹Íû»¯ºÏÎïµÄ¿Ú·þÉúÎïʹÓöÈ¡£¡£¡£¡£¡£¡£ÔÚCaco-2ϸ°û×÷ÓýÔÚÉøÍ¸¾Û̼Ëáõ¥Ä¤ÉÏʱ£¬£¬ £¬£¬Äܹ»ÐγÉÒ»¸öµ¥²ãÉÏÆ¤Ï¸°û£¬£¬ £¬£¬¿ÉÒÔÓÃÓÚÄ£ÄâÈ˳¦ÉÏÆ¤Ï¸°ûµÄµÄÐÎ̬£¬£¬ £¬£¬Ðγɶ¥Ä¤²à(apical,AP)ºÍ»ùµ×Íâ²à(basolateral,BL)½á¹¹£¬£¬ £¬£¬ÄÜÔÚ¶¥Ä¤Íâò·Ö½â³öË¢×´ÔµÈÞë¡£¡£¡£¡£¡£¡£ÓëPAMPA£¨Æ½ÐÐÈ˹¤Ä¤ÉøÍ¸ÊÔÑ飩Ïà±È£¬£¬ £¬£¬Caco-2ϸ°û¾ßÓÐͨÁ¿½ÏµÍ£¬£¬ £¬£¬±¾Ç®½Ï¸ßµÄÌØµã£¬£¬ £¬£¬È»ºóCaco-2ϸ°û¿ÉÒÔͬʱ¿ìËÙɸѡ´óÅúÁ¿Ò©Î£¬ £¬£¬ËùÐèÒªµÄÒ©Á¿½ÏÉÙ£¬£¬ £¬£¬Ïà±È¶¯ÎïÄ£×Ó¶øÑÔ£¬£¬ £¬£¬ÊÇÏà¶Ô¾­¼ÃʡʱµÄÑ¡Ôñ¡£¡£¡£¡£¡£¡£²¢ÇÒ£¬£¬ £¬£¬coca-2¿ÉÒÔ±í´ï³¦µÀתÔËÌåºÍø£¬£¬ £¬£¬ÓпÉÄÜÕ¹Íû×Ô¶¯×ªÔ˺ÍÓжàÖÖתÔËÌåµÄÒ©ÎïÏ໥×÷Óᣡ£¡£¡£¡£¡£

ÍÆ¼öÔĶÁ£º    Ê²Ã´ÊÇCaco-2ϸ°ûÄ£×Ó£¿£¿£¿

ÒÔÏÂΪCaco-2ϸ°ûÉøÍ¸ÐÔÊÔÑéµÄÒ»Ñùƽ³£°ì·¨£º

(1) Ê×ÏÈǰ´¦Öóͷ£ÐèÒª½«Caco-2ϸ°û×÷ÓýÔÚ¶à¿×͸Ã÷µÄ×÷ÓýĤÉÏ£¬£¬ £¬£¬ÐγÉÒ»¸öϸ°ûµ¥²ã£¬£¬ £¬£¬Í¨³£ÐèÒª14-28Ìì¡£¡£¡£¡£¡£¡£ÔÚ×÷ÓýÀú³ÌÖУ¬£¬ £¬£¬È·±£Caco-2ϸ°ûµÖ´ïÒ»¶¨µÄ·Ö½âˮƽ£¬£¬ £¬£¬ÒÔ¸üºÃµØÄ£Ä⳦ÉÏÆ¤Ï¸°û²ã¡£¡£¡£¡£¡£¡£

(2) ½«´ý²âµÄ»¯ºÏÎï¼ÓÈëµ½HBSSÖУ¬£¬ £¬£¬ÈÃÆäÓëCaco-2ϸ°û½Ó´¥¡£¡£¡£¡£¡£¡£

(3) ÈÃϸ°ûÔÚ·õÓýÏäÖÐÒԺ㶨µÄζȡ¢Êª¶ÈºÍCO2Ũ¶ÈÏÂ×÷ÓýÒ»¶Îʱ¼ä£¬£¬ £¬£¬Í¨³£Îª2Сʱ¡£¡£¡£¡£¡£¡£

(4) ÔÚ·õÓý¿¢Êºó£¬£¬ £¬£¬»®·ÖÍøÂçÉϲãÒº£¨ÔÚϸ°ûÉÏ·½£©ºÍϲãÒº£¨Í¨Ï꾡°û²ã½øÈë¿×϶ĤÏ·½£©¡£¡£¡£¡£¡£¡£

ʹÓúÏÊʵļ¼Êõ£¬£¬ £¬£¬ÀýÈç¸ßЧҺÏàÉ«Æ×·¨£¨HPLC£©»òÒºÏàÖÊÆ×ÁªÓ÷¨£¨LC-MS£©£¬£¬ £¬£¬ÕÉÁ¿ÑùÆ·Öл¯ºÏÎïµÄŨ¶È¡£¡£¡£¡£¡£¡£

(5) ͨ¹ý½ÏÁ¿ÉϲãÒººÍϲãÒºÖл¯ºÏÎïµÄŨ¶È£¬£¬ £¬£¬ÅÌË㻯ºÏÎïµÄ͸¹ýÂÊ¡¢ÎüÊÕËÙÂÊÒÔ¼°ÆäËûÏà¹Ø²ÎÊý¡£¡£¡£¡£¡£¡£Ò©ÎïÔÚ Caco-£²Ï¸°ûµ¥²ãÄ£×ÓÖеıí¹ÛÉøÍ¸ÏµÊý£¨apparent permeability coefficient £¬£¬ £¬£¬Papp £©µÄÅÌËã £ºPapp=dCr/dt¡ÁVr¡Á1/A ¡Á1/C£° ¡£¡£¡£¡£¡£¡£ Pappµ¥Î»Îª cm/s ¡£¡£¡£¡£¡£¡£

Caco-2ϸ°ûÉøÍ¸ÐÔÊÔÑé¿ÉÒÔÌṩÓйػ¯ºÏÎïÔÚÄ£Ä⳦µÀÌõ¼þϵÄÎüÊÕÌØÕ÷µÄÖ÷ÒªÐÅÏ¢¡£¡£¡£¡£¡£¡£Í¨¹ýÕÉÁ¿»¯ºÏÎïͨÏ꾡°û²ãµÄÄÜÁ¦£¬£¬ £¬£¬ÆÀ¹ÀÆä±»ÎüÊÕµ½Ñ­»·ÏµÍ³ÖеÄDZÁ¦£¬£¬ £¬£¬²¢Õ¹ÍûÆäÔÚÌåÄÚµÄÒ©´ú¶¯Á¦Ñ§ÐÐΪ¡£¡£¡£¡£¡£¡£Õâ¹ØÓÚÒ©ÎïÑз¢ºÍ¿Ú·þÒ©ÎïµÄÉúÎïʹÓÃ¶ÈÆÀ¹ÀºÜÊÇÒªº¦¡£¡£¡£¡£¡£¡£¿ÉÊÇÈÔÈ»ÐèÒª×¢ÖØ£¬£¬ £¬£¬Caco-2ϸ°ûÉøÍ¸ÐÔÊÔÑéÊÇÒ»ÖÖÌåÍâÒªÁ죬£¬ £¬£¬ËäÈ»Äܹ»ÌṩÓÐÓõIJο¼Êý¾Ý£¬£¬ £¬£¬µ«ÔÚÏÖʵӦÓÃÖÐÈÔÐèÒªÁ¬ÏµÆäËûÒòËØ×ÛºÏÆÀ¹À»¯ºÏÎïµÄÎüÊÕÐÔÄܺÍÉøÍ¸ÐÔ¡£¡£¡£¡£¡£¡£

ÃÀ¸ß÷ÔÚÒ©´ú¶¯Á¦Ñ§ÌåÍâÑо¿·½ÃæÓÐÁè¼ÝÊ®¾ÅÄêµÄÏà¹ØÂÄÀú£¬£¬ £¬£¬¿ÉÌṩÌåÍâÑо¿°üÀ¨´úлÎȹÌÐÔ¡¢P450ÓÕµ¼ºÍÒÖÖÆ¡¢´úл;¾¶Ñо¿¡¢´úл²úÆ·ÅжϵÈÑо¿ÏîÄ¿£¬£¬ £¬£¬Éæ¼°µÄ¶¯ÎïÓдóÊó¡¢Ð¡Êó¡¢Íᢹ·¡¢ºï×ӵȡ£¡£¡£¡£¡£¡£Ã¿ÄêÍê³ÉÁè¼Ý20¸öÐÂÒ©ÁÙ´²Ç°DMPKÉ걨Ñо¿£¬£¬ £¬£¬Ã¿Äê´óÓÚ2000¸ö»¯ºÏÎïµÄÌåÄÚPKɸѡ¡£¡£¡£¡£¡£¡£×÷Ϊһվʽ×ÛºÏЧÀÍÆ½Ì¨£¬£¬ £¬£¬ÃÀ¸ß÷ÖÂÁ¦ÓÚһֱ̽Ë÷ÏȽøµÄ¼¼ÊõºÍÒªÁ죬£¬ £¬£¬ÒÔÖª×ã¿Í»§ÔÚ̽ÌÖÐÂÒ©Ñз¢µÄÐèÇ󣬣¬ £¬£¬Ò»Á¬Ìṩ¸ü¸ßЧ¡¢¸ßÐԼ۱ȵÄÑз¢Ð§ÀÍÖúÁ¦¿Í»§¼ÓËÙÐÂÒ©Ñз¢Àú³Ì¡£¡£¡£¡£¡£¡£¸³ÄÜÈ«ÇòÏàÖúͬ°é£¬£¬ £¬£¬¾ÛÁ¦ÖйúÁ¢Ò죬£¬ £¬£¬ÎªÈËÀ࿵½¡Ð¢Ë³ÊµÁ¦£¡

ÍÆ¼öÔĶÁ£º
²Î¿¼ÎÄÏ×£º

1. Xiu-wei Yang, Xiao-da Yang, Ying Wang, Lian Ma, Yue Zhang, Xiao-gai Yang, Kui Wang. Establishment of Caco-2 cell monolayer model and standard operation procedure for assessing intestinal absorption of chemical components of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2007, 5(6): 634-641.

2. Íõɯ, Áõ˹ç÷, ¶¡ÅôÃô, ÅÓÔÂóÏ, ÌÕÖ¾, & ÍõÈç·å. (2020). ÌåÍâÄ£×ÓÔÚÖÐÒ©´úлÑо¿ÖеÄÓ¦ÓÃ. PROGRESS IN PHARMACEUTICAL SCIENCES, 44(2), 119-132.

Ïà¹ØÐÂÎÅ
Éè¼ÆºÏ³ÉºÍÆÀ¹ÀÓÃÓÚÖÎÁÆÇ°ÏßÏÙ°©µÄCBPäå½á¹¹ÓòÒÖÖÆ¼Á¡£¡£¡£¡£¡£¡£PKÆÀ¹À¡¢¸Î΢Á£ÌåÎȹÌÐԲⶨºÍCaco-2ÉøÍ¸ÐԲⶨͨ¹ýÃÀ¸ß÷¾ÙÐÐ
2023-07-05
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer mortalities in men. CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Researchers designed 1-(Indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer. Pharmacokinetic properties evaluation were analyzed by Medicilon. Liver microsomal stability assay were performed at Medicilon. Caco-2 permeability assay was analyzed by Medicilon.
TRIM24ºÍBRPF1Êǰ©Ö¢µÄDZÔÚÖÎÁưеã¡£¡£¡£¡£¡£¡£Y08624ÊÇÒ»ÖÖÐÂÐÍTRIM24/BRPF1Ë«ÖØÒÖÖÆ¼Á£¬£¬ £¬£¬¾ßÓÐÓÅÒìµÄCaco-2ÉøÍ¸ÐÔ¡£¡£¡£¡£¡£¡£Caco-2 ÉøÍ¸ÐԲⶨͨ¹ýÃÀ¸ß÷¾ÙÐÐ
2023-07-06
TRIM24 (tripartite motif-containing protein 24) and BRPF1 (bromodomain and PHD finger containing protein 1) are epigenetics ¡°readers¡±and potential therapeutic targets for cancer and other diseases. Y08624 (Compound 20l) is a new TRIM24/BRPF1 dual inhibitor. Y08624 displays reasonable Caco-2 permeability. Caco-2 permeability assay was performed by Medicilon.
´Óϸ°û×÷Óýµ½Êý¾ÝÆÊÎö£¬£¬ £¬£¬ÊÖ°ÑÊÖ²ð½âCaco-2ʵÑéÈ«Á÷³Ì
2025-11-19
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿